In melanoma preclinical studies, EZH2 overexpression has been implicated in the escape of immune surveillance, silencing of tumor suppressors and apoptosis pathways, and shaping the interactions between melanoma cells and the microenvironment8–11. The gene discussed is EZH2; the disease is melanoma.